WO2013167959A1 - Myrrh based composition for otological use - Google Patents

Myrrh based composition for otological use Download PDF

Info

Publication number
WO2013167959A1
WO2013167959A1 PCT/IB2013/000897 IB2013000897W WO2013167959A1 WO 2013167959 A1 WO2013167959 A1 WO 2013167959A1 IB 2013000897 W IB2013000897 W IB 2013000897W WO 2013167959 A1 WO2013167959 A1 WO 2013167959A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
myrrh
oil
weight
Prior art date
Application number
PCT/IB2013/000897
Other languages
English (en)
French (fr)
Inventor
Andrea Lacorte
Germano Tarantino
Original Assignee
Junia Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Junia Pharma Srl filed Critical Junia Pharma Srl
Publication of WO2013167959A1 publication Critical patent/WO2013167959A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/63Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Definitions

  • the present invention relates to a pharmaceutical composition or a medical device or a food supplement comprising a myrrh extract, preferably a myrrh oil extract or a myrrh hydroglyceric extract, for otological use or for oral use or for topical use, preferably for treating pediatric patients.
  • a myrrh extract preferably a myrrh oil extract or a myrrh hydroglyceric extract
  • the present invention relates to a myrrh extract, preferably a myrrh oil extract or a myrrh hydroglyceric extract, for relieving and/or preventing irritative states of pharynx (nasopharynx, oropharynx, laryngopharynx and hypopharynx), throat (pharyngitis and tonsillitis) and/or ear (otitis), which might be caused by infections (treatment of oropharynx infections) or by colds and/or allergies.
  • pharynx nasopharynx, oropharynx, laryngopharynx and hypopharynx
  • throat pharyngitis and tonsillitis
  • otitis otitis
  • Myrrh is an aromatic gum resin extracted from a tree or bush of the genus Commiphora, of the family of Burseraceae, it can also be found in powder form. There are about fifty species of Commiphora, distributed on the shores of the Red Sea, in Senegal, in Madagascar and in India. The species which is most used for producing myrrh is Commiphora yrrha (spread in Somalia, Ethiopia, Sudan, Arab peninsula). At the end of summer the shrub covers with flowers and on the stem appear a series of nodules bleeding myrrh as yellow droplets which are harvested once dried in the air. Myrrh is used today as extract or essential oil, the latter being obtained by distillation. Myrrh has an analgesic activity.
  • a task of the present invention is to be able to provide a composition based on a myrrh extract having a high anti-inflammatory, analgesic and antiseptic activity, a high emollient power and a remarkable barrier protective effect.
  • Another task of the present invention is to be able to provide a composition based on a myrrh extract which can relieve and/or prevent irritative states of pharynx (nasopharynx, oropharynx, laryngopharynx and hypopharynx), throat (pharyngitis and tonsillitis) and/or ear (otitis), which might be caused by infections (treatment of oropharynx infections) or by colds and/or allergies.
  • pharynx nasopharynx, oropharynx, laryngopharynx and hypopharynx
  • throat pharyngitis and tonsillitis
  • otitis which might be caused by infections (treatment of oropharynx infections) or by colds and/or allergies.
  • An aim of the present invention is to provide a pharmaceutical composition, a medical device or a food supplement comprising a myrrh extract, preferably a myrrh oil extract or a myrrh hydroglyceric extract, for otological use or for oral use or for topical use, which have a higher therapeutic activity than products on the market.
  • a myrrh extract preferably a myrrh oil extract or a myrrh hydroglyceric extract
  • Another aim of the present invention is to provide a pharmaceutical composition, a medical device or a food supplement comprising a myrrh extract, preferably a myrrh oil extract or a myrrh hydroglyceric extract, for otological use or for oral use or for topical use; said pharmaceutical composition or said medical device or said food supplement being easily administered for treating patients, e.g. pediatric patients.
  • a myrrh extract preferably a myrrh oil extract or a myrrh hydroglyceric extract
  • Still another aim of the present invention is to provide a pharmaceutical composition, a medical device or a food supplement comprising a myrrh extract, preferably a myrrh oil extract or a myrrh hydroglyceric extract, for otological use or for oral use or for topical use; said pharmaceutical composition or said medical device or said food supplement being able to create a protective film for ensuring a barrier effect.
  • An object of the present invention is a pharmaceutical composition, a medical device or a food supplement (in short the compositions of the present invention) for use in the preventive or curative treatment of irritative states of pharynx (nasopharynx, oropharynx, laryngopharynx and hypopharynx), throat (pharyngitis and tonsillitis) and/or ear (otitis), which might be caused by infections (treatment of oropharynx infections) or by colds and/or allergies, as claimed in the appended claims.
  • compositions of the present invention refers to a “pharmaceutical composition or a medical device or a food supplement”.
  • the Applicant has prepared a pharmaceutical composition, a medical device and a food supplement (the compositions of the present invention) for use in the preventive and/or curative treatment of irritative states of pharynx, throat and/or ear comprising or alternatively consisting of a myrrh extract, a vegetable oil and at least one antioxidant.
  • Said compositions of the present invention are for use in the treatment of otitis and pharyngitis.
  • Said myrrh extract is selected from the group comprising or alternatively consisting of a myrrh aqueous extract, a myrrh alcoholic extract, a myrrh hydroglyceric extract or a myrrh oil extract.
  • said extract is a myrrh oil extract or a myrrh hydroglyceric extract.
  • said myrrh oil extract is a myrrh extract in soya bean oil.
  • compositions of the present invention comprise said myrrh extract in a concentration of 5 to 50% of myrrh extract, with respect to the total weight of the extract; still more preferably, said extract has a concentration of 10 to 20% of myrrh extract, with respect to the total weight of the extract.
  • compositions of the present invention further comprise an oil or an oil mixture.
  • Oils are vegetable oils.
  • said oil is selected from the group comprising or alternatively consisting of olive oil, sunflower oil, corn oil or soya oil.
  • the vegetable oil is olive oil.
  • compositions of the present invention further comprise one or more substances having an antioxidant activity or a suspension comprising one or more substances having an antioxidant activity.
  • the substances are selected from the group comprising or alternatively consisting of vitamins with an antioxidant activity.
  • the substance with antioxidant activity is selected from the group comprising or alternatively consisting of vitamin E, tocopherols, preferably DL-alpha-tocopherol, tocotrienols or mixtures thereof and rosemary extracts.
  • the antioxidant can be in the form of an oily suspension containing a concentrate of tocotrienols and/or tocopherols alone or in combination with squalene and/or carotenoids and/or phytosterols and/or coenzyme Q10; said suspension contains an amount of compounds ranging from 0.1 to 10% by weight.
  • the rosemary extract is a rosemary hydroglyceric extract.
  • compositions of the present invention for use as medicament in the treatment of ear diseases and inflammations, comprise said myrrh extract in an amount of 5 to 25% by weight, with respect to the total weight of the composition; preferably in an amount of 10 to 15% by weight, with respect to the total weight of the composition; said oil in an amount of 95 to 75% by weight, with respect to the total weight of the composition; preferably in an amount of 90 to 85% by weight, with respect to the total weight of the composition; and said antioxidant in an amount of 0.1 to 2% by weight, with respect to the total weight of the composition; preferably in an amount of 0.1 to 0.8% by weight, with respect to the total weight of the composition.
  • compositions of the present invention for use as medicament in the treatment of ear diseases and inflammations, in the form of ear drops comprise olive oil, preferably in an amount of 75 to 90% by weight, with respect to the weight of the composition, a myrrh extract in oil, preferably an extract in soya oil, in a concentration ranging from 10 to 20% by weight, with respect to the weight of the composition, and DL- alpha-tocopherol or a suspension of tocopherols and tocotrienols, preferably in an amount of 0.1 to 3% by weight, with respect to the weight of the composition.
  • 100 grams of composition comprise 14.5 grams of a myrrh extract in oil, 0.60 grams of a composition of tocopherols and tocotrienols (trade name Tocomin® by Carotech®), and 74.90 of olive oil.
  • 100 grams of composition comprise 80 grams of olive oil, 15 grams of a myrrh extract in oil, and 5 grams of rosemary oil extract.
  • 100 grams of composition in the form of ear drops comprise 10 to 20 grams of a myrrh extract in soya oil, preferably 12 to 16 grams, 90 to 80 grams of a vegetable oil such as olive oil, preferably 88 to 84 grams.
  • Said 100 grams of composition in the form of drops are added with DL-alpha- tocopherol in an amount of 0.10 grams to 0.30 grams, preferably 0.15 to 0.20 grams, to obtain the final composition.
  • This composition is applied in an amount of 2 to 3 drops in each ear 1 to 2 times per day.
  • the daily dose (6 drops/ear) comprises 24 mg of myrrh extract in oil and 0.4 mg of DL-alpha- tocopherol.
  • the compositions of the present invention, for use as medicament further comprise an emulsifier selected from the group comprising xanthan gum, carboxymethylcellulose and polysorbate.
  • 100 grams of composition comprise 15 grams of a myrrh extract in oil, preferably a myrrh extract in soya oil; 0.5 grams of rosemary dry extract and the rest consists of glycerin, water, soya lecithin, polysorbate 80.
  • compositions of the present invention are for topical use, e.g. in the form of cream; or for otological use, e.g. in the form of ear drops; or for oral use, e.g. in the form of solution, syrup, mouth wash, spray solution.
  • compositions of the present invention can be in the form of an aqueous suspension comprising an emulsifier selected among xanthan gum, carboxymethylcellulose and/or polysorbate. Once applied, this composition can form on the application surface a patina or a film or a sort of solid coating thanks to the presence of carboxymethylcellulose. The composition thus performs a soothing action and creates a highly effective barrier effect.
  • compositions of the present invention can be in the form an oral spray solution.
  • 10 to 16% by weight of fructose preferably 12 to 14%
  • 50 to 70% by weight of water preferably 55 to 65%
  • 10 to 18% by weight of glycerol or vegetable glycerin preferably 12 to 15%.
  • Said solution can contain water, myrrh hydroglyceric extract, fructose, glycerol or vegetable glycerin, citric acid, preservatives and sweeteners.
  • compositions of the present invention are useful for relieving, preventing and/or treating irritative states of pharynx (nasopharynx, oropharynx, laryngopharynx and hypopharynx), throat (pharyngitis and tonsillitis) and/or ear (otitis), which might be caused by infections (treatment of oropharynx infections) or by colds and/or allergies.
  • the oily composition of the present invention containing a myrrh oil extract enables a longer persistence of drops in the ear, thus allowing the composition to perform its action effectively.
  • oily substances can perform a coadjutant action in the prevention and removal of wax plugs, if any.
  • the oily composition of the present invention is apt for use in the symptomatic treatment of otitis in pediatric patients. 2 to 3 drops are administered 1 to 2 times per day for a treatment period of 5 to 7 days.
  • the oily composition of the present invention is already effective in the symptomatic treatment of otitis within 48 hours from the first treatment consisting in the administration of 2 to 3 drops 1 to 2 times per day.
  • the composition for ear use is in liquid or suspension or emulsion form and comprises or alternatively consists of a myrrh extract in soya oil, an olive oil and DL-alpha-tocopherol.
  • composition of the present invention containing a myrrh oil extract was tested for the symptomatic treatment of otitis in pediatric patients.
  • composition in the form of ear drops contains (for 100 grams of composition): - 14.5 grams of a myrrh extract in soya oil,
  • composition in the form of drops were added with 0.25 grams of DL-alpha-tocopherol to obtain a final composition (tested composition) of 100.25 grams.
  • Otitis media-externa 2 drops TID, for 5 days disappeared 48 hours after first administration
  • a pharmaceutical composition or a medical device or a food supplement comprising a myrrh extract, a vegetable oil and at least one antioxidant for use in the preventive and/or curative treatment of irritative states of pharynx, throat and/or ear, which might be caused by infections or colds and/or allergies.
  • composition for use according to PE1 for the treatment of pharyngitis and otitis.
  • said oil is selected from the group consisting of olive oil, sunflower oil, corn oil or soya oil;
  • said at least one antioxidant is selected from the group consisting of vitamins with an antioxidant activity, preferably vitamin E; tocopherols, preferably DL-alpha-tocopherol; tocotrienols or mixtures thereof, and a rosemary extract, preferably a rosemary hydroglyceric extract.
  • composition for use according PE4 wherein said at least one antioxidant is an oily suspension containing a concentrate of tocotrienols and tocopherols alone or in combination with squalene and/or carotenoids and/or phytosterols and/or coenzyme Q10; said suspension has an extract concentration of 20 to 50%.
  • composition for use according to one of the PEs above wherein said extract has a concentration of 5 to 50% of myrrh extract, with respect to the total weight of the extract; still more preferably said extract has a concentration of 10 to 20% of myrrh extract, with respect to the total weight of the extract.
  • said myrrh extract is present in an amount of 5 to 25% by weight, with respect to the total weight of the composition; preferably, in an amount of 10 to 15% by weight, with respect to the total weight of the composition,
  • said oil is present in an amount of 95 to 75% by weight, with respect to the total weight of the composition; preferably, in an amount of 90 to 85% by weight, with respect to the total weight of the composition, and
  • said at least one antioxidant is present in an amount of 0.1 to 2% by weight, with respect to the total weight of the composition; preferably, in an amount of 0.2 to 0.8% by weight, with respect to the total weight of the composition.
  • composition for use according to any one of the PEs above wherein said composition comprises olive oil, preferably in an amount of 75 to 90% by weight, with respect to the weight of the composition, a myrrh extract in oil, preferably in a concentration of 10 to 20% by weight, with respect to the weight of the composition, and DL-aipha-tocopherol or a suspension of tocopherols and tocotrienols, preferably in an amount of 0.1 to 3% by weight, with respect to the weight of the composition.
  • composition for use according to any one of the PEs above wherein said composition further comprises an emulsifier selected from the group comprising xanthan gum, carboxymethylcellulose, polysorbate.
  • emulsifier selected from the group comprising xanthan gum, carboxymethylcellulose, polysorbate.
  • composition for use according to one of the PEs above wherein said composition is for topical, otological or oral use, preferably in the form of drops or spray solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PCT/IB2013/000897 2012-05-09 2013-05-10 Myrrh based composition for otological use WO2013167959A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000790A ITMI20120790A1 (it) 2012-05-09 2012-05-09 Composizione a base di mirra per uso otologico
ITMI2012A000790 2012-05-09

Publications (1)

Publication Number Publication Date
WO2013167959A1 true WO2013167959A1 (en) 2013-11-14

Family

ID=46582903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/000897 WO2013167959A1 (en) 2012-05-09 2013-05-10 Myrrh based composition for otological use

Country Status (2)

Country Link
IT (1) ITMI20120790A1 (it)
WO (1) WO2013167959A1 (it)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757095A (zh) * 2008-10-20 2010-06-30 刘新光 一种治疗中耳炎的中药
WO2010089046A1 (de) * 2009-02-09 2010-08-12 Doris Barnikol-Keuten In situ haft-gelbildende zubereitungen, insbesondere zur topischen anwendung auf befeuchtete haut/schleimhaut

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757095A (zh) * 2008-10-20 2010-06-30 刘新光 一种治疗中耳炎的中药
WO2010089046A1 (de) * 2009-02-09 2010-08-12 Doris Barnikol-Keuten In situ haft-gelbildende zubereitungen, insbesondere zur topischen anwendung auf befeuchtete haut/schleimhaut

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEN-ERIK VAN WYK, MICHAEL WINK: "Medicinal Plants of the World", 1 January 2004, TIMBER PRESS, Portland, Oregon, USA, ISBN: 0-88192-602-7, article "Commiphora myrrha", pages: 111, XP002689227 *
DATABASE WPI Week 201060, Derwent World Patents Index; AN 2010-J98410, XP002689226 *

Also Published As

Publication number Publication date
ITMI20120790A1 (it) 2013-11-10

Similar Documents

Publication Publication Date Title
ES2206195T3 (es) Productos farmaceuticos, suplementos alimentarios y composiciones cosmeticas que comprenden un acido graso y jengibre.
US20190008907A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
US20090155392A1 (en) Methods and Systems for Sublingual Guarana Administration
US20130052271A1 (en) Compositions and Methods for Treating Pain
US9775872B2 (en) Topical pharmaceutical bases for preventing viral diseases
JP2002500209A (ja) 或る種のジテルペン類そして医薬品として使用するためにこれらを含有するCurcumaamadaの抽出物及び濃縮物
Amra et al. Therapeutic benefits of natural oils along with permeation enhancing activity
US11826394B2 (en) Method of using a rosemary extract composition for promoting a healthy body weight
US20160113990A1 (en) Herbal formulation of an edible oral turmeric, its derivatives & other ingredients for the management of inflammation and chronic pain
Belkhodja et al. In vitro and in vivo anti-inflammatory potential of eucalyptus globulus essential oil
Kriplani et al. Recent patents on anti-cancer potential of helenalin
US9579357B1 (en) Therapeutic compositions
US20160129063A1 (en) Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
CN101249130B (zh) 一种戒烟并缓解戒烟综合症的药用或保健组合物
US20100003351A1 (en) Compositions comprising rhodiola rosea and methods of use thereof
AU2016307998B2 (en) Composition comprising tannins
WO2013167959A1 (en) Myrrh based composition for otological use
WO2010002406A1 (en) Compositions comprising rhodiola rosea and methods of use thereof
CN103202881A (zh) 一种治疗皮疹的外用剂组合物
US20170020946A1 (en) Analgesic compositions and methods of use
US20130316017A1 (en) Oral Composition for the Treatment of Acne
IT201900010800A1 (it) Composizione contenente estratto di fico d'india in olio di serenoa per il mantenimento della funzionalità della prostata
ES2581180B1 (es) Uso de aloe oral para la mejora capilar
Gupta et al. Nutraceuticals in Periodontal Health and Diseases in Dogs and Cats
WO2024028897A1 (en) A topical composition based on beta caryophylene for the management of pain and inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13730310

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 17/03/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13730310

Country of ref document: EP

Kind code of ref document: A1